Bone metastasis current status

Amura has developed low nanomolar inhibitors of cathepsin K with excellent selectivity (greater than a hundred fold) versus closely related homologs.  These AMcore™ based candidates exhibit high oral exposure, low in vivo clearance and cross-species inhibitory activity, thereby facilitating efficacy studies in disease related animal models.  A study, designed to evaluate compounds in an athymic nude mouse model of bone metastasis, demonstrated that oral administration of compound resulted in a reduction in osteolytic lesion area.

Amura has licensing opportunities for its AMcore™-based programmes.